Madrigal Pharmaceuticals Inc (MDGL NASDAQ) stock market data APIs
$396.6337
53.35(13.5%)
as of November 3, 2026
Try our APIs with
free plan!
Madrigal Pharmaceuticals Inc Financial Data Overview
Price chart is built with
Anychart
Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company was founded in 2016 and is headquartered in West Conshohocken, Pennsylvania.
Prev. Close
396.6337
Open
449.9838
High
479.9153
Low
390.3876
52 wk Range
387.33-615
Market Cap
9 157 M
Shares Outstanding
23 104 K
Revenue
1 428 M
EPS
-5.08
Beta
-0.997
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Madrigal Pharmaceuticals Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Madrigal Pharmaceuticals Inc data using free add-ons & libraries
Get Madrigal Pharmaceuticals Inc Fundamental Data
Madrigal Pharmaceuticals Inc Fundamental data includes:
- Net Revenue: 1 428 M
- EBITDA: -151 116 000
- Earnings Per Share: -5
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
Get Madrigal Pharmaceuticals Inc Earnings data
Corporate Events Calendar & News package for
$
19.99
/mo.
What’s included:
- Latest Release: 2026-11-03
- EPS/Forecast: -1.09
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Madrigal Pharmaceuticals Inc News
New
Madrigal Pharmaceuticals (MDGL) Turns Profitable, Is The 42% Undervaluation Case Still Convincing?
Madrigal Pharmaceuticals (MDGL) flipped to profitability in the third quarter of 2026, reporting net income of US$55.44 million after a net loss of US$114.19 million in the prior year period. The lat...
Madrigal Pharmaceuticals Inc (MDGL) Q3 2026 Earnings Call Highlights: First Profitable Quarter ...
This article first appeared on GuruFocus. Net Sales (Q3 2026): $431.3 million, up 50% year-over-year. Year-to-Date Net Sales: $1.1 billion, crossing the $1 billion milestone. Annualized Run Rate: Mor...
Madrigal (MDGL) Q3 Earnings and Revenues Beat Estimates
Madrigal (MDGL) came out with quarterly earnings of $1.83 per share, beating the Zacks Consensus Estimate of a loss of $1.09 per share. This compares to a loss of $5.08 per share a year ago. These fig...
Madrigal: Q3 Earnings Snapshot
WEST CONSHOHOCKEN, Pa. (AP) — WEST CONSHOHOCKEN, Pa. (AP) — Madrigal Pharmaceuticals Inc. (MDGL) on Tuesday reported third-quarter earnings of $55.4 million. The West Conshohocken, Pennsylvania-b...
Get Madrigal Pharmaceuticals Inc fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
Best Offer
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.